Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/24
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVenturesGlobeNewsWire • 11/13/23
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 11/13/23
Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023GlobeNewsWire • 11/06/23
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® TechnologyGlobeNewsWire • 11/06/23
Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's During Symposium at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD)GlobeNewsWire • 10/04/23
Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare ConferenceGlobeNewsWire • 09/19/23
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?Zacks Investment Research • 09/18/23
Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 08/08/23
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023GlobeNewsWire • 08/01/23